247 related articles for article (PubMed ID: 8693445)
1. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.
Costello CM; O'Connor CM; Finlay GA; Shiels P; FitzGerald MX; Hayes JP
Thorax; 1996 Jun; 51(6):619-23. PubMed ID: 8693445
[TBL] [Abstract][Full Text] [Related]
2. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Hodson ME
Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
[TBL] [Abstract][Full Text] [Related]
3. alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis.
O'Connor CM; Gaffney K; Keane J; Southey A; Byrne N; O'Mahoney S; Fitzgerald MX
Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1665-70. PubMed ID: 8256917
[TBL] [Abstract][Full Text] [Related]
4. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice.
Cantin AM
Am J Respir Crit Care Med; 1998 Feb; 157(2):464-9. PubMed ID: 9476859
[TBL] [Abstract][Full Text] [Related]
5. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
8. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations.
Aronoff SC; Quinn FJ; Carpenter LS; Novick WJ
J Pediatr; 1994 Dec; 125(6 Pt 1):992-7. PubMed ID: 7996376
[TBL] [Abstract][Full Text] [Related]
9. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
10. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis.
Attucci S; Gauthier A; Korkmaz B; Delépine P; Martino MF; Saudubray F; Diot P; Gauthier F
J Pharmacol Exp Ther; 2006 Aug; 318(2):803-9. PubMed ID: 16627747
[TBL] [Abstract][Full Text] [Related]
11. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
12. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
13. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
14. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
Cantin AM; Berthiaume Y; Cloutier D; Martel M
Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Shak S; Capon DJ; Hellmiss R; Marsters SA; Baker CL
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9188-92. PubMed ID: 2251263
[TBL] [Abstract][Full Text] [Related]
17. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase.
Brandt T; Breitenstein S; von der Hardt H; Tümmler B
Thorax; 1995 Aug; 50(8):880-2. PubMed ID: 7570441
[TBL] [Abstract][Full Text] [Related]
18. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis.
Amin N; Dozor AJ
Pediatr Pulmonol; 1994 Sep; 18(3):150-4. PubMed ID: 7800431
[TBL] [Abstract][Full Text] [Related]
19. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum.
Dubois AV; Gauthier A; Bréa D; Varaigne F; Diot P; Gauthier F; Attucci S
Am J Respir Cell Mol Biol; 2012 Jul; 47(1):80-6. PubMed ID: 22343221
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum.
Rochat T; Pastore FD; Schlegel-Haueter SE; Filthuth I; Auckenthaler R; Belli D; Suter S
Eur Respir J; 1996 Nov; 9(11):2200-6. PubMed ID: 8947060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
